Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) released its earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.48), Zacks reports. The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%.
Xenetic Biosciences Stock Performance
XBIO opened at $3.60 on Thursday. The business’s fifty day moving average is $4.00 and its 200-day moving average is $4.00. The firm has a market cap of $5.54 million, a P/E ratio of -1.35 and a beta of 2.17. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.20.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Further Reading
- Five stocks we like better than Xenetic Biosciences
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- How to Use the MarketBeat Dividend Calculator
- Aluminum Tariff Woes: Between 2 Stocks, 1 Shines Brighter
- 10 Best Airline Stocks to Buy
- Semtech Rallies on Earnings Beat—Is There More Upside?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
